Role of mTOR inhibitor in cholangiocarcinoma cell progression

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 854-860

  Moolthiya, Penpak ^a   Tohtong, Rutaiwan ^a   Keeratichamroen, Siriporn ^a   Leelawat, Kawin ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b RAJAVITHI HOSPITAL   (Thailand)

Author keywords

Cholangiocarcinoma; mTOR inhibitor; RAD001

Indexed keywords

EVEROLIMUS; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ACTIN POLYMERIZATION; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL CULTURE; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL SIGNALING ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NICK END LABELING; PHENOTYPE; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84892994601     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1799     Document Type: Article

References (36)

1. Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S and Kosuge T: One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg244: 240-247, 2006.
2. Leelawat K, Leelawat S, Narong S and Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13: 1561-1568, 2007.
3. Alvarez M, Roman E, Santos ES and Raez LE: New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther7: 1423-1437, 2007.
4. Yuan ZQ, Sun M, Feldman RI, et al: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene19: 2324-2330, 2000.
5. Burnett PE, Barrow RK, Cohen NA, Snyder SH and SabatiniDM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95: 1432-1437, 1998.
6. Beugnet A, Wang X and Proud CG: Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem 278: 40717-40722, 2003.
7. Sehgal SN, Baker H and Vézina C: Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28: 727-732, 1975.
8. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC and Meric-Bernstam F: Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15: 257-266, 2008.
9. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
10. Di Paolo S, Teutonico A, Ranieri E, Gesualdo L and Schena PF: Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. IS J Kidney Dis 49: 462-470, 2007.
11. Oshiro N, Yoshino K, Hidayat S, et al: Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9: 359-366, 2004.
12. Schöniger-Hekele M and Müller C: Pilot study: rapamycin in advanced hepatocellular carcinoma. Aliment Pharmacol Ther32: 763-768, 2010.
13. Okada T, Sawada T and Kubota K: Rapamycin inhibits growth of cholangiocarcinoma cells. Hepatogastroenterology 56: 6-10, 2009.
14. Agarwala SS and Case S: Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15: 236-245, 2010.
15. Rattanasinganchan P, Leelawat K, Treepongkaruna SA, et al: Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World J Gastroenterol 12: 6500-6506, 2006.
16. Cybulski N and Hall MN: TOR complex 2: a signaling pathway of its own. Trends Biochem Sci 34: 620-627, 2009.
17. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
18. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M and Diederich M: An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci 1010: 1-8. 2003.
19. Gao CF, Xie Q, Su YL, et al: Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA 102: 10528-10533, 2005.
20. Pei D and Weiss SJ: Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 271: 9135-9140, 1996.
21. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M and Okada Y: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272: 2446-2451, 1997.
22. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K and QuarantaV: Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 148: 615-624, 2000.
23. Mabuchi S, Altomare DA, Cheung M, et al: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13: 4261-4270, 2007.
24. Brown VI, Fang, JJ, Barr R, Alcorn K, Kim J and Grupp SA: The mTOR inhibitors rapamycin and RAD001 are active in experimental models of ALL and are antagonized by interleukin-7. Blood100: 761a, 2002.
25. Hirashima K, Baba Y, Watanabe M, et al: Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer 106: 876-882, 2012.
26. Ida S, Miki Y, Ono K, et al: Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor. Mol Cell Endocrinol 350: 99-106, 2012.
27. Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S and Tungpradubkul S: Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 9: 3, 2009.
28. Gorshtein A, Rubinfeld H, Kendler E, et al: Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16: 1017-1027, 2009.
29. Thomas G, Siegmann M and Gordon J: Multiple phosphorylation of ribosomal protein S6 during transition of quiescent 3T3 cells into early G1, and cellular compartmentalization of the phosphate donor. Proc Natl Acad Sci USA 76: 3952-3956, 1979.
30. Fitzgerald JP, Nayak B, Shanmugasundaram K, et al: Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6-and 8-production. PLoS One 7: e30712, 2012.
31. Bergmann A: Survival signaling goes BAD. Dev Cell 3: 607-608, 2002.
32. Schürmann A, Mooney AF, Sanders LC, et al: p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 20: 453-461, 2000.
33. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al: Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 91: 231-241, 1997.
34. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, et al: 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6: 41-51, 2000.
35. Cheng EH, Wei MC, Weiler S, et al: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711, 2001.
36. Chen L, Willis SN, Wei A, et al: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403, 2005.